SecBot SecBot

ATTO

Attovia Therapeutics, Inc.
Nasdaq· CIK 0002058707 Biotech & Drug Discovery
$13.83 −0.67 (−4.62%)
Oct 23 4:00 PM ET · prev $14.50
Market cap
$661.9M
Small cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$45.00
+225% · range $30.00–52.00
Since first trade
−36.8%
from $21.90 · Aug 5
30 days
−21.6%
from $17.65
Range since listing
$13.73–25.55
−46% from high · low Oct 16
Avg volume 20D
461.6K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$51.9M
6 buyers · 2 sellers · since Aug 5
Filing reports
17
analyzed by SecBot
SecBot read BULLISH 19 reports · 90 days
Balance 0 bearish · 7 bullish · 12 neutral oldest → newest, height = score
Avg score ·High conf. 18/19
Strongest BULLISH Attovia Therapeutics reported Q2 2026 results with a net loss of $20.7M (vs $14.4M in Q2 2025) and minimal…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    6 insiders bought $52.4M at an average $17.22. 2 insiders sold $425.5K. Price is 20% below their cost.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    28% below its 50-day average.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy4Buy6Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +225%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 31, 2026Citigroup
INITIATE
INITIATEBuy
Aug 31, 2026LifeSci Capital
INITIATE
INITIATEOutperform
Aug 31, 2026Leerink Partners
INITIATE
INITIATEOutperform
Aug 31, 2026RBC Capital
INITIATE
INITIATEOutperform
Aug 31, 2026Morgan Stanley
INITIATE
INITIATEOverweight
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
Short interest
Short Interest: ATTO up 98% to 1.6M shares
Settlement 2026-09-30 | Days to cover: 2.98 | ≈3.61% of shares outstanding (est.)
Sep 28, 2026
FDA
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical…
Sep 3, 2026
Press release
Attovia Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage…
Sep 2, 2026
Earnings
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data…
Aug 6, 2026
Press release
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical…

Insider ledger

Form 4
$52.4M
bought · 6 insiders
$425.5K
sold · 2 insiders
−19.7%
vs their $17.22 cost
DateInsiderTypeValue
Aug 6, 2026
Redmile Group, LLC
10%+ Owner
CONVERT782,854 sh
Aug 6, 2026
Redmile Group, LLC
10%+ Owner
BUY$3.4M
Aug 6, 2026
Redmile Group, LLC
10%+ Owner
BUY$6.8M
Aug 6, 2026
Redmile Group, LLC
10%+ Owner
CONVERT782,854 sh
Aug 6, 2026
Frazier Life Sciences XI, L.P.
10%+ Owner
CONVERT1,749,192 sh
Aug 6, 2026
Frazier Life Sciences XI, L.P.
10%+ Owner
CONVERT1,590,175 sh
Aug 6, 2026
Frazier Life Sciences XI, L.P.
10%+ Owner
CONVERT1,189,940 sh
Aug 6, 2026
Frazier Life Sciences XI, L.P.
10%+ Owner
CONVERT961,322 sh

Earnings setup

Estimates
−$0.50
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.50-$0.50–-$0.50—$0.00
Next Q-$0.52-$0.52–-$0.52—$0.00
Current FY-$3.45-$3.45–-$3.45—$462.5K
Next FY-$2.38-$2.38–-$2.38—$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 8, 2026 SEC
This is a purely administrative amendment (3/A) to a Form 3 initial beneficial ownership filing. The amendment…
3/A — Impact 1/10
Oct 8, 2026 SEC
This is an administrative amendment (Form 3/A) filed by Steven Chan, CFO of Attovia Therapeutics, correcting the…
3/A — Impact 2/10
Sep 30, 2026 Short interest report
Short Interest: ATTO up 98% to 1.6M shares
Settlement 2026-09-30 | Days to cover: 2.98 | ≈3.61% of shares outstanding (est.)
Sep 28, 2026 Press
Attovia Therapeutics announced it will present new clinical, translational, and preclinical data across its pipeline…
Impact 3/10
Sep 2, 2026 SEC
Attovia Therapeutics reported Q2 2026 results with a net loss of $20.7M (vs $14.4M in Q2 2025) and minimal…
PRESS-RELEASE — Impact 7/10
Aug 6, 2026 Insider
Redmile Group, LLC acquired 782,854 shares
10%+ Owner
Aug 6, 2026 Insider
Redmile Group, LLC bought 200,000 shares
10%+ Owner @ $17.00 ($3.4M)
Aug 6, 2026 Insider
Redmile Group, LLC bought 400,000 shares
10%+ Owner @ $17.00 ($6.8M)

SecBot reports

17 filings · 2 press releases · 7 bullish · 0 bearish · 10 neutral
All ATTO filing & press-release reports (19)